Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer

被引:42
|
作者
Flieswasser, Tal [1 ,2 ]
Van Loenhout, Jinthe [1 ]
Freire Boullosa, Laurie [1 ]
Van den Eynde, Astrid [1 ]
De Waele, Jorrit [1 ]
Van Audenaerde, Jonas [1 ]
Lardon, Filip [1 ]
Smits, Evelien [1 ,3 ]
Pauwels, Patrick [1 ,2 ]
Jacobs, Julie [1 ,2 ]
机构
[1] Integrated Personalized & Precis Oncol Network IP, Ctr Oncol Res CORE, B-2610 Antwerp, Belgium
[2] Antwerp Univ Hosp, Dept Pathol, B-2650 Edegem, Belgium
[3] Antwerp Univ Hosp, Ctr Cell Therapy & Regenerat Med, B-2650 Edegem, Belgium
关键词
non-small cell lung cancer; chemotherapy; immunogenic cell death; ENDOPLASMIC-RETICULUM STRESS; CALRETICULIN EXPOSURE; TARGETED THERAPIES; IN-VITRO; CISPLATIN; PEMBROLIZUMAB; EFFICACY; MULTICENTER; ACTIVATION; RESISTANCE;
D O I
10.3390/cells9061474
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The concept of immunogenic cell death (ICD) has emerged as a cornerstone of therapy-induced anti-tumor immunity. To this end, the following chemotherapies were evaluated for their ability to induce ICD in non-small cell lung cancer (NSCLC) cell lines: docetaxel, carboplatin, cisplatin, oxaliplatin and mafosfamide. The ICD hallmarks ATP, ecto-calreticulin, HMGB1, phagocytosis and maturation status of dendritic cells (DCs) were assessed in vitro. Furthermore, an in vivo vaccination assay on C57BL/6J mice was performed to validate our in vitro results. Docetaxel and the combination of docetaxel with carboplatin or cisplatin demonstrated the highest levels of ATP, ecto-calreticulin and HMGB1 in three out of four NSCLC cell lines. In addition, these regimens resulted in phagocytosis of treated NSCLC cells and maturation of DCs. Along similar lines, all mice vaccinated with NSCLC cells treated with docetaxel and cisplatin remained tumor-free after challenge. However, this was not the case for docetaxel, despite its induction of the ICD-related molecules in vitro, as it failed to reject tumor growth at the challenge site in 60% of the mice. Moreover, our in vitro and in vivo data show the inability of oxaliplatin to induce ICD in NSCLC cells. Overall with this study we demonstrate that clinically relevant chemotherapeutic regimens in NSCLC patients have the ability to induce ICD.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 50 条
  • [31] Clozapine Induces Autophagic Cell Death in Non-Small Cell Lung Cancer Cells
    Yin, Yu-Chun
    Lin, Chao-Cheng
    Chen, Tzu-Ting
    Chen, Jen-Yeu
    Tsai, Hui-Ju
    Wang, Chia-Yu
    Chen, Shiow-Yi
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2015, 35 (03) : 945 - 956
  • [32] Jasmonates induce apoptosis and cell cycle arrest in non-small cell lung cancer lines
    Yeruva, Laxmi
    Pierre, Keon J.
    Carper, Stephen W.
    Elegbede, J. Abiodun
    Toy, Beau J.
    Wang, Robert C.
    [J]. EXPERIMENTAL LUNG RESEARCH, 2006, 32 (10) : 499 - 516
  • [33] Commentary: Keeping surgery relevant in oligometastatic non-small cell lung cancer
    Donington, Jessica S.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 157 (04): : 1629 - 1630
  • [34] Effects of dexmedetomidine on A549 non-small cell lung cancer growth in a clinically relevant surgical xenograft model
    Jun, Ji Hae
    Shim, Jae-Kwang
    Oh, Ju Eun
    Kim, Kwang-Sub
    Kwak, Young-Lan
    Soh, Sarah
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [35] Effects of dexmedetomidine on A549 non-small cell lung cancer growth in a clinically relevant surgical xenograft model
    Ji Hae Jun
    Jae-Kwang Shim
    Ju Eun Oh
    Kwang-Sub Kim
    Young-Lan Kwak
    Sarah Soh
    [J]. Scientific Reports, 13
  • [36] In vitro characterization of the effect of nazartinib against non-small cell lung cancer activating clinically relevant EGFR mutants
    Masuzawa, Keita
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    Nukaga, Shigenari
    Hasegawa, Hanako
    Hamamoto, Junko
    Naoki, Katsuhiko
    Soejima, Kenzo
    Betsuyaku, Tomoko
    [J]. CANCER RESEARCH, 2017, 77
  • [37] Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer
    Aguado, Cristina
    Teixido, Cristina
    Roman, Ruth
    Reyes, Roxana
    Gimenez-Capitan, Ana
    Marin, Elba
    Cabrera, Carlos
    Vinolas, Nuria
    Castillo, Sergi
    Munoz, Silvia
    Arcocha, Ainara
    Lopez-Vilaro, Laura
    Sullivan, Ivana
    Aldeguer, Erika
    Rodriguez, Sonia
    Moya, Irene
    Viteri, Santiago
    Cardona, Andres Felipe
    Palmero, Ramon
    Sainz, Cristina
    Mesa-Guzman, Miguel
    Lozano, Maria D.
    Aguilar-Hernandez, Andres
    Martinez-Bueno, Alejandro
    Gonzalez-Cao, Maria
    Gonzalvo, Elena
    Leenders, William P. J.
    Rosell, Rafael
    Montuenga, Luis M.
    Prat, Aleix
    Molina-Vila, Miguel A.
    Reguart, Noemi
    [J]. MOLECULAR ONCOLOGY, 2021, 15 (02) : 350 - 363
  • [38] Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer
    Liu, Jun
    Jia, Jingyi
    Wang, Siqiao
    Zhang, Junfang
    Xian, Shuyuan
    Zheng, Zixuan
    Deng, Lin
    Feng, Yonghong
    Zhang, Yuan
    Zhang, Jie
    [J]. MOLECULES, 2022, 27 (13):
  • [39] Developing an Immunogenic Model of Non Small Cell Lung Cancer
    Laing, S.
    Edwards, S.
    Graham, G.
    Kruspig, B.
    Coffelt, S.
    Strathdee, D.
    Murphy, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S687 - S688
  • [40] Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
    Dean A Fennell
    Charles Swanton
    [J]. EPMA Journal, 2012, 3 (1):